Physician profile
Zahid Hamid
NPI 1972526978
$14,967.16
in general payments reported to CMS, 2019-2025
45 companies · $1,190 in 2025
The $1,190 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,377 · 2020: $3,435 · 2021: $1,864 · 2022: $2,099 · 2023: $1,405 · 2024: $1,595 · 2025: $1,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,130 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,130.07 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardinal Health 110 LLC | $4,400.00 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $1,674.51 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbott Laboratories | $1,473.69 | 2020-2024 | Eterna, Proclaim, Axium |
| Amgen INC. | $830.43 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $695.50 | 2019-2025 | Ozempic, Rybelsus |
| Mannkind Corporation | $540.37 | 2019-2023 | Afrezza |
| Novartis Pharmaceuticals Corporation | $490.22 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $486.46 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Sanofi-Aventis U.S. LLC | $442.66 | 2019-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $404.83 | 2022-2025 | Caplyta |
| Abbvie INC. | $339.88 | 2021-2024 | |
| Lilly USA, LLC | $260.88 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Dexcom, INC. | $239.96 | 2021-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.00 | 2020-2024 | Jardiance |
| Cvrx, INC. | $230.51 | 2024 | Barostim Neo System |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zahid Hamid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.